Vaccine research is a dynamic field focused on understanding, developing, and optimizing vaccines to prevent infectious diseases. The process involves multidisciplinary collaboration between immunologists, virologists, geneticists, and other experts. Research begins with identifying suitable antigens, often proteins or genetic material, from pathogens. Various vaccine platforms, including live attenuated, inactivated, subunit, and mRNA vaccines, are explored to elicit robust immune responses. Preclinical studies involve testing vaccine candidates in animals to assess safety, immunogenicity, and efficacy. Promising candidates progress to clinical trials, where they undergo rigorous testing in human volunteers to evaluate safety, dosage, and effectiveness. Advancements in vaccinology also involve exploring novel adjuvants, delivery methods, and formulations to enhance immune responses and improve vaccine stability. The emergence of new infectious threats, such as the COVID-19 pandemic, highlights the agility and innovation required in vaccine research. Collaborative efforts between academia, industry, and public health organizations continue to drive progress, ensuring the development of safe and effective vaccines to address global health challenges. Ongoing research efforts aim to broaden vaccine applicability, enhance durability, and optimize strategies for equitable global distribution.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States